Available Brands
Did you find this information helpful?
Author Details

Written By
P. Thirumal Reddy
B. Pharm

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 26 Sep 2026 | 08:41 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
ABATACEPT
Last updated on 26 Sep 2026 | 08:41 AM (IST)
ABATACEPT
Background and Date of Approval
Abatacept is a biologic immunomodulatory agent developed to treat autoimmune inflammatory diseases, particularly rheumatoid arthritis and related conditions. It works by regulating overactive immune responses that damage joints and tissues.
Abatacept received U.S. FDA approval in December 2005 for the treatment of rheumatoid arthritis in adults. It was later approved by the European Medicines Agency (EMA) in 2007. Subsequent approvals expanded its use to include juvenile idiopathic arthritis (JIA) and psoriatic arthritis (PsA).
Because it targets T-cell activation, a central mechanism in autoimmune inflammation, Abatacept has become an important option for patients who do not respond adequately to conventional DMARDs or other biologic therapies.
Uses
Abatacept.NMP is used to treat:
Rheumatoid Arthritis (RA) in adults
Psoriatic Arthritis (PsA)
Moderate to severe Juvenile Idiopathic Arthritis (JIA)
Patients who have had an inadequate response to:
Methotrexate
TNF inhibitors
Other DMARDs
It helps reduce joint swelling, stiffness, and pain and prevents joint damage over time.
Abatacept is used only under the guidance of rheumatologists or specialists experienced in the management of autoimmune diseases.
How Abatacept Works
Abatacept works by selectively modulating immune system activity:
1. T-Cell Co-Stimulation Blockade
Abatacept binds to CD80/86 receptors on antigen-presenting cells.
This prevents CD28 activation on T cells.
Without this co-stimulatory signal, T cells do not fully activate.
2. Reduced Immune Inflammation
Decreases inflammatory cytokines.
Lowers immune-driven joint destruction.
Reduces swelling, stiffness, and pain.
3. Long-Term Disease Modification
By preventing T-cell overactivation, Abatacept slows disease progression and helps preserve joint structure and function.
Drug Administration and Dosage Information
Abatacept is available as:
Intravenous (IV) infusion
Subcutaneous injection (not relevant for the powder-for-infusion product)
For Orencia Powder for Infusion:
The dose is based on body weight.
It is administered as a slow IV infusion over 30 minutes.
Infusions are typically given at:
Week 0
Week 2
Week 4
Then every 4 weeks thereafter.
Side Effects
Serious Side Effects:
Severe infections (pneumonia, TB reactivation)
Infusion reactions (breathing difficulty, chest tightness)
Allergic reactions (swelling, rash, hives)
Increased risk of malignancies (rare)
Common Side Effects:
Headache
Dizziness
Nausea
High blood pressure
Cough or respiratory infections
Fatigue
Injection/infusion-site reactions
Joint pain or worsening arthritis symptoms during initial doses
Seek medical care immediately if you experience persistent fever, shortness of breath, or unusual bruising.
Expert tips
Ensure all vaccinations are updated before starting Abatacept.
Do not take Abatacept if you currently have a serious infection.
Inform your doctor if you experience frequent colds or recurrent infections.
Maintain regular follow-up visits to monitor disease activity and blood parameters.
Continue recommended physiotherapy or joint exercises alongside treatment.
Do not stop treatment abruptly unless advised by your doctor.
FAQs
Q1.
It is used to treat rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis by reducing autoimmune inflammation.
Q2.
Most patients notice improvement within 8 to 12 weeks, with continued benefits over months.
Q3.
Only non-live vaccines are allowed. Live vaccines must be avoided.
Q4.
No. It is a biologic immunomodulator that selectively targets T-cell activation.
Q5.
Yes. It is commonly used with methotrexate, but not with other biologic immunosuppressants.
Fact Box
Molecule Name | Abatacept |
Therapeutic Class | Antirheumatic / Immunomodulator |
Pharmacological Class | Selective T-cell Co-stimulation Modulator |
Indications | RA, PsA, JIA |
References
Bristol-Myers Squibb. Abatacept (Abatacept) Prescribing Information https://packageinserts.bms.com/pi/pi_Abatacept.pdf
Schiff M. et al. (2008). Abatacept for rheumatoid arthritis treatment outcomes. Annals of Rheumatic Diseases https://ard.bmj.com/content/67/4/498
American College of Rheumatology (ACR) Guidelines on Biologic DMARDs https://rheumatology.org/clinical-practice-guidelines
Disclaimer
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.






